Brillouet S[au] - Search Results

Year	Number of Results
2010	2
2011	2
2012	2
2014	1
2017	2
2018	1
2019	2
2022	1

1

Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands.

de Medina P, Paillasse MR, Ségala G, Khallouki F, Brillouet S, Dalenc F, Courbon F, Record M, Poirot M, Silvente-Poirot S. de Medina P, et al. Among authors: brillouet s. Chem Phys Lipids. 2011 Sep;164(6):432-7. doi: 10.1016/j.chemphyslip.2011.05.005. Epub 2011 May 27. Chem Phys Lipids. 2011. PMID: 21641337 Review.

2

Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose.

Dierickx LO, Huyghe E, Nogueira D, Zerdoud S, Filleron T, Brillouet S, Delauney B, Montagut J, Bujan L, Plante P, Courbon F. Dierickx LO, et al. Among authors: brillouet s. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):129-37. doi: 10.1007/s00259-011-1929-3. Epub 2011 Sep 10. Eur J Nucl Med Mol Imaging. 2012. PMID: 21909754

3

The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells.

Bauriaud-Mallet M, Vija-Racaru L, Brillouet S, Mallinger A, de Medina P, Rives A, Payre B, Poirot M, Courbon F, Silvente-Poirot S. Bauriaud-Mallet M, et al. Among authors: brillouet s. J Steroid Biochem Mol Biol. 2019 Sep;192:105390. doi: 10.1016/j.jsbmb.2019.105390. Epub 2019 Jun 3. J Steroid Biochem Mol Biol. 2019. PMID: 31170473

4

Evaluation of 2 diuretic 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography imaging protocols for intrapelvic cancer.

Dierickx LO, Dercle L, Chaltiel L, Caselles O, Brillouet S, Zerdoud S, Courbon F. Dierickx LO, et al. Among authors: brillouet s. Q J Nucl Med Mol Imaging. 2019 Sep;63(3):284-291. doi: 10.23736/S1824-4785.17.02912-0. Epub 2017 Mar 29. Q J Nucl Med Mol Imaging. 2019. PMID: 28358186

5

Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.

Brillouet S, Dorbes S, Courbon F, Picard C, Delord JP, Benoist E, Poirot M, Mestre-Voegtlé B, Silvente-Poirot S. Brillouet S, et al. Bioorg Med Chem. 2010 Jul 15;18(14):5400-12. doi: 10.1016/j.bmc.2010.05.031. Epub 2010 May 19. Bioorg Med Chem. 2010. PMID: 20542702

6

Comparison of Two Types of Amino Acid Solutions on ¹⁷⁷Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors.

Lambert M, Dierickx L, Brillouet S, Courbon F, Chatelut E. Lambert M, et al. Among authors: brillouet s. Curr Radiopharm. 2022;15(2):164-172. doi: 10.2174/1874471015666211228123525. Curr Radiopharm. 2022. PMID: 35105299

7

Comparison of an alternative and existing binning methods to reduce the acquisition duration of 4D PET/CT.

Didierlaurent D, Jaudet C, Ribes S, Batatia H, Dierickx LO, Zerdoud S, Brillouet S, Weyts K, Courbon F, Caselles O. Didierlaurent D, et al. Among authors: brillouet s. Med Phys. 2014 Nov;41(11):112503. doi: 10.1118/1.4897612. Med Phys. 2014. PMID: 25370662

8

Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.

Vija Racaru L, Sinigaglia M, Kanoun S, Ben Bouallègue F, Tal I, Brillouet S, Bauriaud-Mallet M, Zerdoud S, Dierickx L, Vallot D, Caselles O, Gabiache E, Pascal P, Courbon F. Vija Racaru L, et al. Among authors: brillouet s. Nucl Med Commun. 2018 Jul;39(7):672-679. doi: 10.1097/MNM.0000000000000850. Nucl Med Commun. 2018. PMID: 29790867 Free PMC article.

9

Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response.

Vija Racaru L, Fontan C, Bauriaud-Mallet M, Brillouet S, Caselles O, Zerdoud S, Bastié D, Vallot D, Caron P, Bardiès M, Courbon F. Vija Racaru L, et al. Among authors: brillouet s. Nucl Med Commun. 2017 Sep;38(9):756-763. doi: 10.1097/MNM.0000000000000705. Nucl Med Commun. 2017. PMID: 28719405 Clinical Trial.

10

Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.

Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, Brillouet S, Canal P, Courbon F, Allal BC. Vergez S, et al. Among authors: brillouet s. Clin Cancer Res. 2010 Sep 1;16(17):4434-45. doi: 10.1158/1078-0432.CCR-09-2795. Epub 2010 Jul 26. Clin Cancer Res. 2010. PMID: 20660574

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results